Lion TCR announces USD20m from Series A financing round.
M2 PHARMA-May 28, 2018-Lion TCR announces USD20m from Series A financing round
(C)2018 M2 COMMUNICATIONS
Singapore biotech company Lion TCR Pte Ltd reported on Sunday the receipt of USD20m under its Series A financing round.
The Series A financing round was led primarily by undisclosed existing investors as well as other new investors: Yashang Capital and Westlake Ventures Capital.
Proceeds from this fundraising will be used by Lion TCR Pte Ltd to advance its on-going clinical trials of its lead candidate LioCyx (personalized HBV specific TCR T cell therapy against HCC) in major hospitals in China and Singapore, as well as for broadening its products pipeline to fight viral-related solid tumors and clearance of chronic hepatitis B.
Hepatocellular carcinoma (HCC) has over 700,000 new cases every year, the world second deadly cancer, of which 80% in Asia Pacific and 50% in China.
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Date:||May 28, 2018|
|Previous Article:||Luye Pharma closes acquisition of signature products Seroquel and Seroquel XR.|
|Next Article:||Indivior updates the regulatory submission of SUBLOCADE Injection for opioid dependence in Australia.|